hig.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Merger and acquisition between small biotech and large pharmaceutical companies - a winning combination?: Case study on the acquisitions of CAT by AstraZeneca and Abgenix by Amgen; MBA thesis in marketing
University of Gävle, Department of Business Administration and Economics.
2008 (English)Independent thesis Advanced level (degree of Master (One Year)), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

This study aims at introducing and describing a novel multi parameter analysis method to identify potential acquisition targets and to qualitatively and quantitatively evaluate the overall match between a target company and its acquirer. The method was tested with two recent real cases involving each an antibody based biotech company and a large fully integrated pharmaceutical company. The model was validated by comparing two independent antibody companies against the real cases, testing if they would have made better targets. It was found out that the in reality acquired companies scored highest, thus proving the validity of the method. One of the four potential targets got the highest scores for both acquirers. Consequently one of the acquired targets was only the second best match. The still independent companies would not have been better targets. The lowest scoring target company did get identical scores for both acquiring companies. Despite the proper prediction of targets, the scoring did not reveal the true underlying motives for the acquisitions, nor could significant parameters be identified to discriminate between target and non-target. This study adds a novel, valuable tool to the still limited arsenal of methods to qualitatively and quantitatively measure a match between target and acquirer solely based on publicly available data.

Place, publisher, year, edition, pages
2008. , 56 p.
Keyword
Merger and acquisition, biotechnology, pharmaceutical industry, monoclonal antibody
National Category
Business Administration
Identifiers
URN: urn:nbn:se:hig:diva-3261Archive number: E3BA: DiVA 004/09OAI: oai:DiVA.org:hig-3261DiVA: diva2:128294
Presentation
(English)
Uppsok
samhälle/juridik
Supervisors
Examiners
Available from: 2009-01-28 Created: 2008-12-15 Last updated: 2009-01-28Bibliographically approved

Open Access in DiVA

fulltext(1218 kB)2974 downloads
File information
File name FULLTEXT01.pdfFile size 1218 kBChecksum SHA-512
415929ce0168d8b1b90f1c4beda16984f9c9fe9604a2c66341f90630f3aeecd7273e7ff989b1b06bee18c98733921985cab9c4d32d63f79a627cc39316386152
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Schmidt, Stefan
By organisation
Department of Business Administration and Economics
Business Administration

Search outside of DiVA

GoogleGoogle Scholar
Total: 2974 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 1903 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf